Inventor · disambiguated record
Panayiotis Stevis
Also filed as: STEVIS PANAYIOTIS · STEVIS PANAYIOTIS E
19 granted patents·7 pending applications·71 citations·filing 2007–2025
94Inventor score
Top patents by PatentIndex Score
26 records- 0194US10618968B2Antigen-binding proteins that activate the leptin receptorREGENERON PHARMA·Filed 2018·Granted Apr 14, 2020·7 cites·34 claims
- 0294US10023644B2Antigen-binding proteins that activate the leptin receptorREGENERON PHARMA·Filed 2016·Granted Jul 17, 2018·14 cites·14 claims
- 0393US9644018B2Antibody modulators of APLNRREGENERON PHARMA·Filed 2015·Granted May 9, 2017·13 cites·11 claims
- 0491US11608381B2Methods of treatment using a leptin receptor agonist antibodyREGENERON PHARMA·Filed 2019·Granted Mar 21, 2023·4 cites·9 claims
- 0591US10253102B2Antigen-binding proteins that activate the leptin receptorREGENERON PHARMA·Filed 2018·Granted Apr 9, 2019·7 cites·29 claims
- 0690US11535675B2Antigen-binding proteins that antagonize leptin receptorREGENERON PHARMA·Filed 2020·Granted Dec 27, 2022·2 cites·25 claims
- 0790US10550192B2Antigen-binding proteins that antagonize leptin receptorREGENERON PHARMA·Filed 2017·Granted Feb 4, 2020·4 cites·24 claims
- 0887US10626173B2Method for treating pathological angiogenesis by administering an antibody that inhibits APLNRREGENERON PHARMA·Filed 2018·Granted Apr 21, 2020·2 cites·20 claims
- 0986US2025051465A1Antigen-binding proteins that activate the leptin receptorREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1085US9353163B2Apelin fusion proteins and uses thereofREGENERON PHARMA·Filed 2014·Granted May 31, 2016·6 cites·15 claims
- 1183US9751921B2Apelin fusion proteins and uses thereofREGENERON PHARMA·Filed 2016·Granted Sep 5, 2017·3 cites·18 claims
- 1283US2024091301A1APLNR Modulators and Uses ThereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1382US10947310B2Fusion protein comprising apelin and an anti-APLNR antibodyREGENERON PHARMA·Filed 2018·Granted Mar 16, 2021·1 cites·20 claims
- 1482US10189901B2Methods for improving cardiac function by administering an antibody that activates APLNRREGENERON PHARMA·Filed 2017·Granted Jan 29, 2019·2 cites·13 claims
- 1581US2025320301A1Methods of treatment using a leptin receptor agonist antibodyREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1679US12275792B2Antigen-binding proteins that activate the leptin receptorREGENERON PHARMA·Filed 2021·Granted Apr 15, 2025·0 cites·14 claims
- 1779US11834500B2Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereofREGENERON PHARMA·Filed 2018·Granted Dec 5, 2023·1 cites·9 claims
- 1879US10155811B2APLNR modulators and uses thereofREGENERON PHARMA·Filed 2014·Granted Dec 18, 2018·2 cites·20 claims
- 1977US12371503B2Methods of treatment using a leptin receptor agonist antibodyREGENERON PHARMA·Filed 2022·Granted Jul 29, 2025·0 cites·12 claims
- 2075US11642390B2Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibodyREGENERON PHARMA·Filed 2021·Granted May 9, 2023·0 cites·18 claims
- 2175US2023235068A1Antigen-binding proteins that antagonize leptin receptorREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2274US11479802B2Assays for screening activity of modulators of members of the hydroxy steroid (17-beta) dehydrogenase (HSD17B) familyREGENERON PHARMA·Filed 2018·Granted Oct 25, 2022·1 cites·7 claims
- 2374US2024158497A1Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2467US7790161B2GDF-9/BMP-15 modulators for the treatment of bone disordersWYETH LLC·Filed 2007·Granted Sep 7, 2010·2 cites·38 claims
- 2567US2020031946A1Antigen-binding proteins that activate the leptin receptorREGENERON PHARMA·Filed 2019·Application pending·0 cites
- 2653US2018030099A1Apelin Fusion Proteins and Uses ThereofREGENERON PHARMA·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Panayiotis Stevis files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →